4,4'-BIS(5-HEXYLTHIOPHEN-2-YL)-2,2'-BIPYRIDINE, 95%, 1g

2-(1-phenylethyl)-1H-pyrrolo[2,3-b]pyridine, 250mg

(3-((4-(Tert-butyl)-2-methylphenoxy)methyl)phenyl)boronic acid, 98%, 5g

4-Bromo-3-chloro-2-fluorobenzyl alcohol, 98%, 1g

1-Ethoxy-2,3-difluoro-4-((1s,4r)-4-propylcyclohexyl)benzene, 98.0%, 25g

Ethyl 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate, 95.0%, 250mg

tert-butyl 2-methyl-3-{[2-(morpholin-4-yl)ethyl]amino}propanoate, 95.0%, 10g

METHYL 2-AMINOIMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE, 95.0%, 100mg

3-Chloropropyldimethylmethoxysilane, 95%, 100g

(S)-3-(3-fluorophenyl)-2-hydroxypropanoic acid, 98%, 250mg

Plan phase PLPHi S100x/1.25 oil immersion infinity corrected IOS objective. Working distance 0.36 mm

6-Bromo-3-methoxy-2-nitropyridine, 98%, 5g

2-Morpholino-N-(4-phenylthiazol-2-yl)acetamide, 90%, 100mg